Tag: lawsuits

Bragar Eagel & Squire, P.C. Litigation Attorney Brandon Walker Encourages Investors Who Suffered Losses In Reckitt (RBGLY) To Contact Him Directly To Discuss Their Options

Bragar Eagel & Squire, P.C. Litigation Partner Brandon Walker Encourages Investors Who Suffered Losses In Sarepta (SRPT) or PetCo (WOOF) To Contact Him Directly To Discuss Their Options

WARREN, N.J., Aug. 01, 2025 (GLOBE NEWSWIRE) -- Tevogen (“Tevogen Bio Holdings Inc.” or “Company”) (Nasdaq: TVGN), today released a letter to stockholders.

WARREN, N.J., Aug. 01, 2025 (GLOBE NEWSWIRE) -- Tevogen Bio Holdings Inc. (“Tevogen” or the “Company) (Nasdaq: TVGN), today announced that it expects to receive $1 million in grant funding to advance Tevogen.AI, its artificial intelligence–powered drug discovery and development program.

LOUISVILLE, Ky., Aug. 01, 2025 (GLOBE NEWSWIRE) -- BrightSpring Health Services, Inc. (“BrightSpring” or the “Company”) (NASDAQ: BTSG), a leading provider of home and community-based health services for complex populations, today announced financial results for the second quarter ended June 30, 2025, and increased Revenue and Adjusted EBITDA¹ guidance.

NOT FOR DISTRIBUTION TO U.S. NEWS WIRE SERVICES OR DISSEMINATION IN THE UNITED STATES

- Expects to reduce 2024 net loss and increase carrying value of assets held for sale
by approximately $2.2 million -
- Expects to increase first quarter 2025 net income by approximately $0.5 million, resulting in a cumulative increase in carrying value of assets held for sale by approximately $2.7 million -
- No change to 2024 or first quarter 2025 Adj. EBITDA -

WARREN, N.J., July 30, 2025 (GLOBE NEWSWIRE) -- Tevogen (“Tevogen Bio Holdings Inc.” or “Company”) (Nasdaq: TVGN), today highlighted the Company’s significant insider ownership of outstanding common stock, as most recently reported on July 10, 2025, on Form 8-K filed with the Securities and Exchange Commission.

PARSIPPANY, N.J., July 29, 2025 (GLOBE NEWSWIRE) -- Avis Budget Group, Inc. (NASDAQ: CAR) announced financial results for second quarter 2025 today. We ended the quarter with revenues of $3.0 billion, net income of $5 million, and Adjusted EBITDA¹ of $277 million.

Stellantis Reports First Half 2025 Results Reflecting External Headwinds and Ongoing Recovery Actions; Financial Guidance Re-Established